Biohaven Pharmaceutical Holding Co Ltd. CEO Vlad Coric's 2018 pay jumps 104% to $7.9M

Biohaven Pharmaceutical Holding Co Ltd. reports 2018 executive compensation

By ExecPay News

Published: April 11, 2019

Biohaven Pharmaceutical Holding Co Ltd. reported fiscal year 2018 executive compensation information on April 11, 2019.

In 2018, five executives at Biohaven Pharmaceutical Holding Co Ltd. received on average a compensation package of $3.6M, a 36% increase compared to previous year.

Average pay of disclosed executives at Biohaven Pharmaceutical Holding Co Ltd.

Vlad Coric, Chief Executive Officer, received $7.9M in total, which increased by 104% compared to 2017. 88% of Coric's compensation, or $6.9M, was in option awards. Coric also received $438K in bonus, $500K in salary, as well as $13K in other compensation.

James Engelhart, Chief Financial Officer, received a compensation package of $3.2M, which increased by 28% compared to previous year. 80% of the compensation package, or $2.6M, was in option awards.

Charles Conway, Chief Scientific Officer, earned $2.8M in 2018, a 72% increase compared to previous year.

Kimberly Gentile, SVP, Clinical Operations, received $2.8M in 2018.

John Tilton, Chief Commercial Officer, earned $1.5M in 2018.